Evidence map›Paper›PMID 20576209›Full record

ArticleClinical and experimental rheumatology

Plasma endogenous enkephalin levels in early systemic sclerosis: clinical and laboratory associations.

Terry A McNearney, K A Sluka, C Ahn, J D Reveille, Michael Fischbach, Maureen D Mayes

Open access · greenAbstract read
PubMed Full text at PMC
In one paragraph

Article in Clinical and experimental rheumatology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.4field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 4 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 1 country.

Terry A McNearneyDivision of Rheumatology-UTMB, 301 University Blvd., Galveston, TX 77555-1165, USA. tmcnearn@utmb.edu
K A Sluka
C Ahn
J D Reveille
Michael Fischbach
Maureen D Mayes
The University of Texas Health Science Center at Houston · USClinical Research Management · USThe University of Texas at San Antonio · USThe University of Texas Medical Branch at Galveston · US

Funding

ZOLLINGER-ELLISON SYNDROME AND DUODONAL ULCER DISEASEM01RR000073 · NCRR · UNIVERSITY OF TEXAS MEDICAL BR GALVESTON · PI RAJI, MUKAILA A · 1985 to 2009
$31.3M
ZOLEDRONATE VS AREDIA IN MULTIPLE MYELOMA/BREAST CANCER W /BONE DISORDERSM01RR001346 · NCRR · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI ESCAMILLA, MICHAEL A · 1985 to 2008
$23.1M
Zolmitriptan challenge and human performance testingM01RR002558 · NCRR · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI SCHULTZ, STANLEY G · 1985 to 2006
$10.3M
Role of TGF-beta and CTGF Signaling Transgenic Mouse Models of SclerodermaP50AR054144 · NIAMS · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI MAYES, MAUREEN MAUREEN · 2006 to 2010
$7.7M
Transgenic animal models for fibrotic diseaseP50AR044888 · NIAMS · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI ARNETT, FRANK C · 1997 to 2005
$6.6M
Central contributions to pathobiology of fibromyalgiaR01AR052316 · NIAMS · UNIVERSITY OF IOWA · PI SLUKA, KATHLEEN A · 2005 to 2009
$1.5M
NEUROBIOLOGY OF CHRONIC MUSCLE PAINR01NS039734 · NINDS · UNIVERSITY OF IOWA · PI SLUKA, KATHLEEN A · 1999 to 2003
$696k
NCRR NIH HHS M01 RR000073NCRR NIH HHS M01-RR00073NCRR NIH HHS M01 RR001346NCRR NIH HHS M01 RR002558NCRR NIH HHS M01-RR01346NCRR NIH HHS M01-RR02558NIAMS NIH HHS AR052316NIAMS NIH HHS P50 AR044888NIAMS NIH HHS P50 AR054144NIAMS NIH HHS P50AR054144NIAMS NIH HHS P50AR44888NIAMS NIH HHS R01 AR052316NINDS NIH HHS NS39734NINDS NIH HHS R01 NS039734PHS HHS K0202201
6 · The paper itself

Abstract

objectiveMet- and leu-enkephalins are endogenous opioid neuropeptides with potent analgesic, vasoactive, immunomodulatory and anti-apoptotic properties. We hypothesised that clinical or immunological variables of early systemic sclerosis (SSc) might be correlated to plasma enkephalin levels.

methodsPlasma samples were collected at study entry of the Genetics versus Environment in Scleroderma Outcomes Study (GENISOS) cohort (early SSc, n=116). Plasma met-enkephalin and leu-enkephalin levels (microg/ml) were measured by high performance liquid chromatography (HPLC) and correlated to clinical and laboratory parameters in the GENISOS database. Statistical analyses were performed by nonparametric Wilcoxon rank sum tests and Pearson correlation coefficients.

resultsSignificantly lower plasma met-enkephalin levels were associated with anti-topoisomerase-I seropositivity (6+8.3 vs. 14.9+22.8 microg/ml, p=0.02). Plasma leu-enkephalin levels were significantly higher in SSc patients with digital pulp loss (95.6+130 vs. 64.9+101 microg/ml, p=0.02). Lower mean plasma met-enkephalin levels and inversely higher leu-enkephalin levels were noted in SSc patients with Raynaud's phenomena (p=NS).

conclusionThe associations of plasma enkephalin levels to immunologic or clinical pathologies may underscore their vasogenic or fibrogenic significance and potential as therapeutic targets in early SSc.

Indexed as

AutoantibodiesChromatography, High Pressure LiquidDNA Topoisomerases, Type IEnkephalin, LeucineEnkephalin, MethionineFemaleHumansMaleMiddle AgedNeurotransmitter AgentsScleroderma, DiffuseScleroderma, LimitedAutoantibodiesDNA Topoisomerases, Type IEnkephalin, LeucineEnkephalin, MethionineNeurotransmitter Agents

Identifiers

PMID20576209
PMCPMC3192018
OpenAlexW185362044

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.